BPC-157 vs TB-500: Evidence Comparison

Summary

BPC-157 and TB-500 are the two peptides most often discussed for tissue repair research, and they work through different mechanisms — angiogenic and growth-factor signalling versus actin sequestration and cell migration. Both share the same critical limitation: essentially all supporting evidence is preclinical, from rodent models, with no controlled human trials.

Last reviewed 2026-09-01

What it is

BPC-157 is a synthetic 15–amino-acid sequence derived from a gastric protein; TB-500 is a synthetic fragment corresponding to the active region of thymosin beta-4, a naturally abundant actin-binding protein.

BPC-157 research began in Croatian laboratories in the 1990s, largely from a single research group. Thymosin beta-4 was studied clinically for corneal and dermal wound healing before TB-500 entered informal use.

BPC-157 is a partial sequence of body protection compound; TB-500 corresponds to the actin-binding domain of thymosin beta-4.

They are the two most frequently discussed repair peptides, and the comparison usefully illustrates how thin the human evidence base is for both.

How it works

In plain terms

BPC-157 appears to help build new blood vessels and support growth-factor signalling in injured tissue. TB-500 acts on the cell's internal scaffolding, helping cells move into a wound. Different jobs, both preclinical.

Technical detail

BPC-157 has been reported to upregulate VEGFR2 signalling and the nitric oxide system, modulate the FAK-paxillin pathway, and influence growth hormone receptor expression in tendon fibroblasts in rodent models. TB-500 derives from thymosin beta-4, the primary G-actin sequestering protein in mammalian cells; it regulates actin polymerisation, supporting cell migration, and has been reported to have angiogenic and anti-inflammatory activity. Thymosin beta-4 itself progressed to human trials for corneal and dermal wounds; the synthetic fragment has not.

Pathways involved

BPC-157: VEGFR2, nitric oxide system, FAK-paxillin
TB-500: G-actin sequestration and actin polymerisation dynamics
Both: reported angiogenic and anti-inflammatory effects in rodent models

Current research

Laboratory research

Cell and tissue work exists for both. Thymosin beta-4's actin-binding role is definitively established; BPC-157's proposed mechanisms rest on a narrower literature.

Animal research

BPC-157 has a substantial rodent literature covering tendon, muscle, ligament and gastrointestinal injury, though it originates disproportionately from a small number of related research groups — an independent replication problem. TB-500 and thymosin beta-4 animal work covers cardiac, corneal and dermal repair.

Human research

No controlled human trials exist for either BPC-157 or TB-500. Thymosin beta-4 — the parent protein, not the fragment — reached human trials for corneal and dermal wound healing with mixed results. Neither peptide is approved anywhere; both are prohibited by WADA.

Ongoing research

Independent replication of the rodent findings is the missing step for both.

What is being investigated

Tendon and ligament repair in rodent models
Gastrointestinal mucosal protection (BPC-157)
Cell migration and wound closure (TB-500)
Angiogenesis in injury models

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

No controlled human trial data exists for either peptide
BPC-157's animal literature has a concentrated-source and replication problem
TB-500 is a fragment, and human data on the parent protein does not transfer to it
Both are prohibited by WADA in competitive sport
Neither is approved for human use in any jurisdiction; research-only status is not a technicality

Evidence ratings

Laboratory studies

Moderate

Thymosin beta-4 actin biology strong; BPC-157 mechanisms narrower.

Animal studies

Moderate

Extensive for BPC-157 but with replication concerns.

Human studies

None

No controlled trials for either compound.

Head-to-head data

None

No study has compared them directly.

Comparisons

MOTS-c vs SS-31

Two mitochondrial peptides compared.

References

[1]BPC-157 preclinical literature — PubMed, 1990s–present
[2]Thymosin beta-4 and actin regulation — PubMed, 1990s–present
[3]Thymosin beta-4 clinical trials — ClinicalTrials.gov, various
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

Which has more evidence, BPC-157 or TB-500?+

BPC-157 has more published animal work, but it comes disproportionately from a small set of related research groups, and neither has human trial data.

What is the mechanistic difference?+

BPC-157 is associated with angiogenic and growth-factor signalling; TB-500 acts through actin sequestration and cell migration.

Is TB-500 the same as thymosin beta-4?+

No. TB-500 is a synthetic fragment corresponding to the active region; the full protein has separate, more advanced human research.

Are either approved for human use?+

No. Neither is approved in any jurisdiction, and both are on the WADA prohibited list.

Has anyone compared them head to head?+

No controlled study has compared them directly in any species.

Why is BPC-157's animal literature criticised?+

A large share originates from a small number of related groups, and independent replication has been limited.

Did thymosin beta-4 work in human trials?+

Corneal and dermal wound healing trials produced mixed results; it did not establish clear efficacy.

Do they have known safety data?+

No systematic human safety data exists for either, which is itself a substantive limitation.

Continue your research

BPC-157 research

TB-500 research

Peptide research hub